IL6 and cancer: Further investigations are warranted based on the correlation between serum IL-6 levels and abnormalities in these metabolic pathways, indicating their potential as novel therapeutic targets in cancer. However, it has been reported that prospective studies continuously assessing serum IL-6 levels in OSCC patients are important for further understanding its potential as a biomarker and its association with disease progression [25].